Supercharge Targeting FcRn & FcγR Pathways via Fc Optimization
Understand Mechanism of Action, Maximize Efficacy & Therapeutic Window, & Evaluate Long-Term Clinical Outcomes of Fc Receptor Pathway Targeting Biologics in Autoantibody Mediated Disease
The field of FcRn receptor targeting is gaining ground-breaking speed as Argenx, Janssen, UCB and Immunovant compete to tackle myasthenia gravis and biopharma invest in transformative immunological therapy for autoimmune diseases as the next big drug opportunity.
The 3rd Fc Receptor Pathway Targeted Therapies Summit will once again feature unmissable conversations to advance targeting FcR and the subsequent generation of Fc manipulation since real-world proof and clinical value are now at the industry's fingertips.
Join 100+ of your colleagues at the 3rd Fc Receptor Pathway Targeted Therapies Summit - from the fields of immunology, antibody engineering, pharmacology, toxicology, and immuno-oncology for three days of content that is unmatched in its scope, all focused on the optimization of FcRn, FcγR, and novel Fc.
Put your stake in the ground to revolutionise autoimmune illness and position yourself in front of the next wave of blockbuster drug development.
Download the full Event Guide here - https://ter.li/pye2xb